Poly (ADP-ribose) polymerase inhibitor exposure reduces ovarian reserve followed by dysfunction in granulosa cells

Area of Science:

• Reproductive Biology
• Oncology
• Pharmacology

Background:

• Poly (ADP-ribose) polymerase (PARP) inhibitors are increasingly used in cancer therapy.
• The impact of PARP inhibitors on reproductive health, particularly ovarian function, remains largely unknown.
• Understanding these effects is crucial for patients of reproductive age undergoing PARP inhibitor treatment.

Purpose of the Study:

• To investigate the effects of the PARP inhibitor olaparib on ovarian function and fertility.
• To evaluate both in vitro and in vivo impacts of olaparib exposure on ovarian cells and overall reproductive capacity.

Main Methods:

• In vitro studies involved exposing ovarian and granulosa cell cultures to olaparib, followed by gene expression analysis (RT-PCR), histology, and hormone assays.
• In vivo studies administered olaparib to mice, assessing in vitro fertilization (IVF) rates, follicle counts, and molecular markers.
• Ovarian function was evaluated before, during, and after olaparib treatment cessation.

Main Results:

• Olaparib exposure decreased the expression of granulosa cell markers and estradiol production in vitro.
• Histological examination revealed atretic changes and follicle depletion in both in vitro and in vivo models.
• Olaparib reduced oocyte retrieval and IVF fertilization rates, which were reversible upon treatment cessation.

Conclusions:

• Olaparib demonstrates significant toxicity to ovarian function.
• The observed effects on ovarian cells, follicle depletion, and reduced fertility are concerning.
• Reversibility of effects after drug cessation offers potential therapeutic considerations but highlights the need for careful patient monitoring.